CARBOPROST TROMETHAMINE INJECTION, USP SOLUTION

Страна: Канада

мова: англійська

Джерело: Health Canada

Активний інгредієнт:

CARBOPROST (CARBOPROST TROMETHAMINE)

Доступна з:

DR REDDY'S LABORATORIES LTD

Код атс:

G02AD04

ІПН (Міжнародна Ім'я):

CARBOPROST

Дозування:

250MCG

Фармацевтична форма:

SOLUTION

Склад:

CARBOPROST (CARBOPROST TROMETHAMINE) 250MCG

Адміністрація маршрут:

INTRAMUSCULAR

Одиниць в упаковці:

15G/50G

Тип рецепту:

Prescription

Огляд продуктів:

Active ingredient group (AIG) number: 0133100001; AHFS:

Статус Авторизація:

APPROVED

Дата Авторизація:

2022-09-02

Характеристики продукта

Page 1 of 19
PRODUCT MONOGRAPH
PR
CARBOPROST TROMETHAMINE INJECTION, USP
250 mcg / mL carboprost (as carboprost
tromethamine)
For Intramuscular Use
PROSTAGLANDIN
MANUFACTURED BY:
DR. REDDY’S LABORATORIES LTD.,
Bachupally -500 090 India
IMPORTED AND DISTRIBUTED BY:
DR. REDDY’S LABORATORIES CANADA INC.,
Mississauga, ON, Canada, L4W 4Y1
DATE OF PREPARATION:
September 2, 2022
CONTROL NO. 246759
Page 2 of 19
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................................
3
SUMMARY OF PRODUCT INFORMATION
............................................................................................
3
INDICATIONS AND CLINICAL
USE........................................................................................................
3
CONTRAINDICATIONS
.............................................................................................................................
3
WARNINGS AND PRECAUTIONS
...........................................................................................................
3
ADVERSE REACTIONS
.............................................................................................................................
6
DRUG
INTERACTIONS
...........................................................................................................................
8
DOSAGE AND ADMINISTRATION
..........................................................................................................
9
OVERDOSAGE
............................................................................................................................................
9
ACTION AND CLINICAL PHARMACOLOGY
........................................................................................
9
STORAGE AND STABILITY
...................................................................................................................
10
DOSAGE FORMS, COMPOSITION AND PACKAGING
...............................................................